Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Sarcoma Alliance for Research through Collaboration
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
progressive, recurrent or refractory Ewing's sarcoma, or recurrent or refractory osteosarcoma, synovial sarcoma, rhabdomyosarcoma, or other sarcomas of the following sub-types: alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma and myxoid liposarcoma;
Cohort 3 only: age must be \>= 2 and \<= 21 years
You may not be if
clinically significant unrelated systemic illness which would compromise the participant's ability to tolerate the investigational agent, or interfere with the study procedures or results;
known hypersensitivity to any of the components of R1507 or prior hypersensitivity reactions to monoclonal antibodies;
treatment (within the past 2 weeks) with pharmacologic doses of corticosteroids or other immunosuppressive agents;
current or prior therapy with insulin-like growth factor (IGF) inhibitor (monoclonal or specific kinase inhibitor);
history of solid organ transplant;
other malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer;
active central nervous system disease
Clareo Health | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
